The Prescription For HuajiJianpi On Cellular Immune Function Of Primary Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization

ObjectiveThrough clinical controlled study and experimental research to approach the effect of prescription for HuajiJianpi on Primary Hepatocellular Carcinoma patients' cellular immune function after Transcatheter Arterial Chemoembolization.Materials and Methods69 patients with Primary Hepatocellular Carcinoma were randomly divided into two groups according to the numbers.A group of patients(34 cases) received TACE combined with prescription for HuajiJianpi.B group of patients(35 cases) were treated by TACE alone.We compared the proportions of subcellular groups of T lymphocytic cells,NK cells,NKT cells,NKG2D in the PBMC of the two groups,and tested the cytotoxicity of PBMC in vitro.The objective effect and quality of life were evaluated.Results1.Immunological cell function:In the A group after treatment,the percentages of CD4,CD56,CD3CD56 were significantly raised(P＜0.01),but that of CD8 was obviously reduced(P＜0.01).Comparison between A and B group after treatment on the percentages of CD4,CD56,CD3CD56,A group was higher than B group(P＜0.01).But the percentage of CD8 was lower than B group(P＜0.01).2.The percentage of NKG2D in PBMC:The percentage of NKG2D increased respectively to(54.23±3.17)%,(26.86±3.29)%in PBMC of the two groups after treatment,A group was higher than B group(P＜0.01).3.Cytotoxicity of PBMC in vitro:Comparison between A and B group after treatment on the cytotoxicity of PBMC to HepG2,A group was obviously stronger than B group(P＜0.01).The percentages of cytotoxicity were(74.21±2.65)%,(51.31±3.37)%.4.Objective effect:The effective rates of A and B group were 61.76%and 60% respectively.There was no statistically significant difference between the two groups(P＞0.05).5.Quality of life:The scores were 47.68±7.24 and 40.06±9.00 in the two groups after treatment.The quality of life was significantly improved in the A group(P＜0.05).Conclusions1.Prescription for HuajiJianpi can enhance cellular immune function for Primary Hepatocellular Carcinoma patients after TACE.2.Prescription for HuajiJianpi can increase NKG2D ratio and cytotoxicity of PBMC to HepG2.3.Prescription for HuajiJianpi can better quality of life for Primary Hepatocellular Carcinoma patients after TACE.4.Prescription for HuajiJianpi couldn't increase toxicity for Primary Hepatocellular Carcinoma patients after TACE.